Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1917-1921

  Takeda, Shuso ^a   Misawa, Koichiro ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA RESORCYLIC ACID; CANNABIDIOLIC ACID; CANNABIS; CARBOXYLIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIBENZOPYRAN DERIVATIVE; DICLOFENAC; HYDROXYL GROUP; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAN DERIVATIVE; SALICYLIC ACID; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; IC 50; METHYLATION; PRIORITY JOURNAL;

CANNABINOIDS; CANNABIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR STRUCTURE;

CANNABIS;

EID: 50049113509     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020909     Document Type: Article

References (31)

1. Aramaki H, Tomiyasu N, Yoshimura H, and Tsukamoto H (1968) Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull 16:822-826.
2. Burstein S, Levin E, and Varanelli C (1973) Prostaglandins and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol 22:2905-2910.
3. Burstein SH (1999) The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 82:87-96.
4. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178.
5. DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55:625-631.
6. Formukong EA, Evans AT, and Evans FJ (1988) Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L. Inflammation 12:361-371.
7. Hinz B and Brune K (2002) Cyclooxygenase-2 - 10 years later. J Pharmacol Exp Ther 300:367-375.
8. Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, and Monahan JB (2003) Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol 63:870-877.
9. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
10. Johnson JL, Wimsatt J, Buckel SD, Dyer RD, and Maddipati KR (1995) Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch Biochem Biophys 324:26-34.
11. Klein TW and Newton CA (2007) Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 601:395-413.
12. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, and Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866-12872.
13. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, et al. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648. [Erratum in Nature (1997) 385:555].
14. Luong C, Miller A, Barnett J, Chow J, Ramesha C, and Browner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3:927-933.
15. Mancini JA, Riendeau D, Falgueyret JP, Vickers PJ, and O'Neill GP (1995) Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem 270:29372-29377.
16. Markey CM, Alward A, Weller PE, and Marnett LJ (1987) Quantitative studies of hydroperoxide reduction by prostaglandin H synthase. Reducing substrate specificity and the relationship of peroxidase to cyclooxygenase activities. J Biol Chem 262:6266-6279.
17. O'Banion MK, Sadowski HB, Winn V, and Young DA (1991) A serum- and glucocorticoidregulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266:23261-23267.
18. Picot D, Loll PJ, and Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243-249.
19. Razdan RK (1986) Structure-activity relationships in cannabinoids. Pharmacol Rev 38:75-149.
20. Russo E and Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234-246.
21. Seeram NP, Bourquin LD, and Nair MG (2001) Degradation products of cyanidin glycosides from tart cherries and their bioactivities. J Agric Food Chem 49:4924-4929.
22. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, and Yamada H (2006) Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34:1277-1282.
23. Taura F, Sirikantaramas S, Shoyama Y, Shoyama Y, and Morimoto S (2007) Phytocannabinoids in Cannabis sativa: recent studies on biosynthetic enzymes. Chem Biodivers 4:1649-1663.
24. Tsai WJ, Shiao YJ, Lin SJ, Chiou WF, Lin LC, Yang TH, Teng CM, Wu TS, and Yang LM (2006) Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett 16:4440-4443.
25. Turner CE, Elsohly MA, and Boeren EG (1980) Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169-234.
26. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96:7563-7568. [Erratum in Proc Natl Acad Sci U S A (1999) 96:9666].
27. Watanabe K, Motoya E, Matsuzawa N, Funahashi T, Kimura T, Matsunaga T, Arizono K, and Yamamoto I (2005) Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206:471-478.
28. Watanabe K, Narimatsu S, Gohda H, Yamamoto I, and Yoshimura H (1988) Formation of similar species to carbon monoxide during hepatic microsomal metabolism of cannabidiol on the basis of spectral interaction with cytochrome P-450. Biochem Pharmacol 37:4719-4726.
29. Xie WL, Chipman JG, Robertson DL, Erikson RL, and Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 88:2692-2696.
30. Yamaori S, Ukena E, Fujiyama N, Funahashi T, Kimura T, Yamamoto I, Ohshima T, Matsumura K, Oda M, and Watanabe K (2007) Nafamostat is hydrolysed by human liver cytosolic long-chain acyl-CoA hydrolase. Xenobiotica 37:260-270.
31. Yamauchi T, Shoyama Y, Aramaki H, Azuma T, and Nishioka I (1967) Tetrahydrocannabinolic acid, a genuine substance of tetrahydrocannabinol. Chem Pharm Bull 15:1075-1076.